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Appendix Table, http://wwwnc.cdc.gov/EID/article/22/2/ 
15-1292-Techapp1.pdf).). P. falciparum infection was de-
tected in 2 Anopheles species: 1 (12.5%) of 8 An. ininii and 
1 (5.0%) of 19 An. nuneztovari s.l. mosquitoes collected; 
P. vivax infection was found in 1 (5.5%) of 19 An. nunezt-
ovari s.l. mosquitoes.
In September 2013, another malaria outbreak occurred 
3 weeks after the deployment of 15 soldiers in Dagobert 
(4.06028°N, -53.70667°E; Figure). The attack rate among 
these soldiers was 53.3% (8/15): 7 P. vivax infections and 
1 co-infection with P. vivax and P. falciparum. Mosqui-
toes were collected 3 months later by using human landing 
catches during 5 consecutive days. The area had been free 
of illegal gold mining activities since the 15 soldiers were 
deployed. A total of 321 Anopheles mosquitoes were col-
lected in this location; 95.6% were identified as the same 
4 species as in the Eau Claire mosquito collection (on-
line Technical Appendix Table). Only 1 specimen (0.4%, 
1/282), An. darlingi mosquito, was infected with P. vivax.
These results suggest a high level of malaria transmis-
sion involving An. darlingi and other Anopheles species as 
primary vectors of malaria in the rainforest. The findings 
probably highlight malaria hyperendemicity in communi-
ties of undocumented gold miners, who are often mobile 
and pose a challenge for controlling malaria and other in-
fectious diseases in the region. Indeed, these gold miners 
could reintroduce malaria in areas where competent vectors 
exist in the coastal part of French Guiana and in Surinam 
and Brazil, which border French Guiana. This potential for 
transmission could seriously threaten the success of ma-
laria elimination programs in the Guiana Shield. Further 
studies are needed to better evaluate malaria epidemiology 
in these undocumented populations to determine how best 
to adapt strategies to control malaria transmission in this 
subregion of South America.
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To the Editor: The wide spread of Enterobacteriaceae 
resistant to last-resource therapeutic options, including 
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extended-spectrum β-lactams, fluoroquinolones, and ami-
noglycosides, has re-ignited interest in old antimicrobial 
drugs, such as fosfomycin (1). Fosfomycin resistance rates 
are generally low (<10%) but substantially higher when 
carbapenemase producers are considered (15%–34%) 
(1–3). Resistance phenotypes have been more thoroughly 
investigated in Escherichia coli and linked to chromosom-
al mutations in the target (murA) or transporter (glpT and 
uhpT) genes or less frequently to plasmid-mediated fosfo-
mycin resistance genes (fosA, fosB, fosC) encoding gluta-
thione S-transferases that inactivate the drug (4). fosA3 is 
the most prevalent gene variant, disseminated mainly in E. 
coli isolates from clinical and nonclinical origins (healthy 
persons, companion and food animals) in countries in Asia 
(China, South Korea, and Japan) (2–6) and only recently 
in a migratory bird in Europe (7). We investigated the oc-
currence and molecular features of 43 fosfomycin-resis-
tant Enterobacteriaceae isolates (21 E. coli, 21 Klebsiella 
pneumoniae, and 1 Morganella morganii). These isolates 
were identified among 461 third-generation cephalosporin-
resistant Enterobacteriaceae isolates from a community 
laboratory in northern Portugal during a 13-month period 
(August 2012–August 2013).
We screened for carriage of plasmidborne fosfomycin 
resistance genes (fosA, fosA3, fosB, fosC2) by PCR and 
sequencing (2,5). Chromosomal mutations in murA, glpT, 
and uhpT were investigated for 9 representative E. coli 
isolates (8) and 7 representative K. pneumoniae isolates 
with variable MICs to fosfomycin (>64 mg/L) by PCR 
and comparison of sequences with reference wild-type 
strains (E. coli ATCC25922 and K. pneumoniae type strain 
JCM1662) (8; this study). Fosfomycin-resistant isolates 
represented 9.3% (43/461) of the collection surveyed dur-
ing the study period, which is in line with rates reported 
for clinical isolates from other countries (2,3). Bacterial 
identification and antimicrobial drug susceptibility testing 
to β-lactams and non–β-lactams were performed by auto-
mated methods and further confirmed by disk diffusion 
and agar dilution (for fosfomycin, MIC cutoff 32 mg/L) 
according to European Committee on Antimicrobial Sus-
ceptibility Testing guidelines (http://www.eucast.org). We 
screened blaESBL genes (blaCTX-M, blaTEM, blaSHV) by PCR 
and sequencing (9).
One (2.3%) of 43 E. coli isolates carried fosA3, 
blaCTX-M-15, and blaTEM-1 and contained mutations in GlpT 
(L297F, T348N, Q443E, E444Q) and UhpT (E350Q) 
(GenBank accession nos. KT832798 and KT832797, re-
spectively), most of which were previously associated 
with fosfomycin resistance (8). This isolate was detected 
in a urine sample from a 61-year-old man who had a clini-
cal history of chronic prostatitis and was associated with 
a urinary tract infection (UTI) acquired after travel to 
Asia (China, Philippines). aac-6’-lb-cr, blaOXA-I, and rmtB 
genes were negative by PCR. This isolate exhibited fos-
fomycin MIC >256 mg/L and was concomitantly resistant 
to cefotaxime, cefepime, aztreonam, ciprofloxacin, gen-
tamicin, kanamycin, netilmycin, streptomycin, sulphon-
amide, tetracycline, tobramycin, and trimethoprim but not 
to carbapenems, amoxicillin/clavulanic acid, or cefoxi-
tin. In other E. coli isolates, fosfomycin resistance phe-
notypes were linked to mutations in transporter proteins 
UhpT (8 isolates, E350Q) and GlpT (3 isolates, premature 
stop codons resulting in truncated proteins of 45, 134, 
or 442 aminoacids [GenBank accession nos. KT832799, 
KT832800, and KT832801, respectively]); however, no 
amino acid changes were detected in K. pneumoniae iso-
lates. The detection of fosA3 in a clinical E. coli isolate 
in Europe is alarming because of its association with 
blaCTX-M-15, which is highly disseminated in Portugal and 
other European Union countries (9), whereas fosfomycin 
is increasingly being used to treat UTIs caused by extend-
ed-spectrum β-lactams–producing E. coli (1).
Strain typing (identification of E. coli phylogroups 
and multilocus sequence typing; http://mlst.warwick.ac.uk/
mlst/) revealed that this isolate belonged to phylogenetic 
group D1 and the sequence type 393 clone (9). This clone 
was not previously detected among fosA3-carrying isolates 
(3,4), but it is distributed worldwide (including Asia) linked 
to community-acquired UTI and multidrug resistance 
patterns (9).
Conjugative assays (solid/broth mating at 24°C/37°C 
using E. coli Hb101 azide and kanamycin resistant as 
recipient) and plasmid typing assessed by PCR-based 
replicon typing, IncFII typing formula (FAB), I-CeuI 
pulsed-field gel electrophoresis, and hybridization (5) 
showed that both fosA3 and blaCTX-M-15 were co-located 
in a conjugative F2:A-:B- plasmid (transconjugant MIC 
to fosfomycin >256 mg/L). Moreover, the genetic en-
vironment of fosA3 was assessed by PCR mapping and 
sequencing (2,6), showing a composite transposon con-
taining an insertion sequence 26 323 bp upstream fosA3; 
the orf1, orf2, and orf3 genes (homologous to regulatory 
ones in K. pneumoniae 342); and an insertion sequence 
(IS) 26 downstream (GenBank accession no. KT734860). 
The genetic platform (IS26 composite transposon) and the 
IncFII plasmid variant (F2:A-:B-) are main vehicles for 
disseminating fosA3 among clinical isolates, companion 
and food animals in Asian countries (3,5,6), or blaCTX-M-15 
worldwide (10). Thus, epidemiologic and molecular data 
suggest that the detection of fosA3 in a clinical isolate in 
Europe is associated with a travel-related infection ac-
quired after international travel to Asia. The acquisition 
of fosA3 by a successful clone and an efficient resistance 
plasmid, which might entail subsequent dissemination 
and alerts to the need of close monitoring of fosfomycin 
resistant isolates, is of particular concern.
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To the Editor: Mycoplasma pneumoniae is a major 
cause of respiratory infections among children and young 
adults and is responsible for up to 40% of all community-
acquired pneumonia. In 2011, an epidemic of M. pneu-
moniae infection was reported in several countries in Eu-
rope and Asia and in Israel that primarily involved adhesin 
P1 type 1 strains and only a few P1 type 2 strains (1,2). The 
spread of M. pneumoniae was polyclonal (1–3), except in 
a few semiclosed settings, such as schools (4). Recently, 
a new adhesin P1 type 2 variant, named 2c, was reported 
(5,6) and accounted for 8.3% of 96 M. pneumoniae–posi-
tive samples in Germany (7).
In 2013, an increase in the number of community-
acquired pneumonia cases was reported in children and 
their adult contacts from 2 towns in Russia separated 
by 45 km, Ozerniy and Duchovshina, during Janu-
ary–March and October–November, respectively. To 
characterize the outbreak in Ozerniy, we collected 13 
throat swabs from 9 symptomatic children and 4 asymp-
tomatic adults who were the parents or grandparents of 
the affected children. All children attended the same 
school and were treated in the same district hospital as 
inpatients or outpatients. In Duchovshina, throat swab 
samples were collected from 17 children and 2 adults. 
The children attended the same school, and the pre-
school-aged children visited the same daycare center 1 
km away. One adult patient was the first aid driver who 
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